Supplementary Information

Targeted nanoparticles release ERK-inhibitor in the hypoxic zone Sensitizes Gemcitabine in Mutant K-Ras-addicted Pancreatic Cancer

Debasmita Dutta[1#], Archana De[2], Arnab Ghosh[2,3#], Raj Shankar Hazra[1], Pratyusha Ghosh[1,2], Snigdha Banerjee[2,3*], Francisco Diaz[4], Sunil P. Upadhyay[2], Mohiuddin Quadir[1]* and Sushanta K Banerjee[2,3]*,

[1]Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND, USA,

[2]Cancer Research Unit, VA Medical Center, Kansas City, MO, USA

[3]Department of Pathology and Laboratory Medicine, Kansas City, KS, USA

[4]Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA

INVENTORY OF SUPPLEMENTARY INFORMATION

Contains supplementary Table S1 and uncut Figures-

Table 1. Linear regression model of tumor weight after four weeks of treatment in mice treated with ERKi NPs, free GEM, ERKi+GEM, or saline injections (control group).

Experimental Condition	Coefficient (grams)[a]	95% CI	P<value
ERKi alone[b]	-0.50	(-2.37, 1.37)	0.58
GEM alone[c]	-1.20	(-3.07, 0.67)	0.19
ERKi+GEM[d]	-2.56	(-4.43, -0.69)	0.01

CI: Confidence interval.

[a]Measures the difference between average tumor weight under the corresponding experimental condition and tumor weight on saline injections.

[b]The dichotomous variable was defined as 1 if the mouse received only ERKi, or 0 otherwise.

[c]The dichotomous variable was defined as 1 if the mouse received only GEM or 0 otherwise.

[d]The dichotomous variable was defined as 1 if the mouse received both ERKi and GEM, or 0 otherwise.

Uncut Figures

Initial membrane immunoreacted with NRP-1 ab